Patent Filing Applications

Further advancement in the Company's RNAi Platform Development

e-therapeutics plc is pleased to announce new patent filings to protect the Company's proprietary RNAi platform technology for liver gene silencing.

The Company has recently filed five new patent applications relating to its innovative GalNAc-conjugated siRNA (short interfering RNA) construct designs, including around stabilising chemical modifications enabling specific hepatocyte (liver cell) targeting.

Since our capital raise in May, we have made excellent progress in all areas of the Company. We expect to present data from our RNAi platform in our Interim Results announcement on Tuesday 26 October, when the in vivo characterisation studies will have been completed.

Ali Mortazavi

Chief Executive Officer